News & Events about Relay Therapeutics Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 41st Annual J.P. ...
Relay Therapeutics, Inc. (NASDAQ:RLAY Get Rating) has received an average recommendation of Moderate Buy from the eight analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold...
Relay Therapeutics, Inc. (NASDAQ:RLAY Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $23.29, but opened at $24.12. Relay Therapeutics shares last traded at $23.99, with a volume of 2,474 shares changing hands. Wall Street Analysts Forecast ...
Ticker Report
4 months ago
Relay Therapeutics, Inc. (NASDAQ:RLAY Get Rating) CEO Sanjiv Patel sold 14,000 shares of the firms stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $23.47, for a total value of $328,580.00. Following the transaction, the chief executive ...